LTB-TREAT: A validated international prognostic model for time to treatment in low tumour burden follicular lymphoma.

Fiche publication

Date publication

août 2026

Journal

British journal of haematology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr ROSSI Cédric

Tous les auteurs :
Barge L, Webb L, Pelecanos A, Waters N, Salvaris R, Lai S, Potezny T, Cashman H, Nguyen-Ngo C, Lee D, Yannakou CK, Hamad N, Chauchet A, Choquet S, Rossi C, Herbin A, Kanagaratnam L, Rodier C, Tam CS, Bhattacharyya A, Cheah CY, Hawkes EA, Morris K, Durot E, Tobin J, Hapgood G

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/42657590

Résumé

Watchful waiting (WW) in low tumour burden follicular lymphoma (LTB FL) defers treatment. There is a need to develop a model to predict time to treatment (TTT). We aimed to develop and externally validate a model for TTT in LTB FL. We conducted a retrospective analysis across eight centres within the Australasian Lymphoma Alliance. Two hundred and twenty-nine patients were included between 2004 and 2022 with a median follow-up of 5.0 years (range 0.5-17.8 years) and a median age was 64 years. All patients were Group d'Etude des Lymphomes Folliculaires (GELF) negative and managed with WW. Elevated lactate dehydrogenase and >4 nodal areas were independent prognostic factors associated with shorter TTT. These factors formed a prognostic model identifying three groups: low 59% (median TTT 6.34 years), intermediate 36% (median TTT 4.08 years), high risk 5% (median TTT 1.49 years) (p < 0.001). There was a higher incidence of serious complications among risk groups (low 7.5% vs. intermediate 13.3% vs. high 25%; p = 0.096). The prognostic value of the LTB-TREAT model was confirmed in an external validation cohort. The low-risk group is predicted to have a prolonged TTT with WW and a high-risk group is predicted to experience early progression in whom treatment should be considered.